9 Endocrinology Headlines You Missed in Q2 2026

The second quarter of 2026 saw an influx of critical approvals from the US Food and Drug Administration (FDA) and a slew of major conferences including the American Diabetes Association (ADA) Scientific Sessions and the Endocrine Society (ENDO) Annual Meeting. Between inhaled insulin’s approval in pediatric patients and the topline efficacy of crinecerfont and retatrutide, all manner of drugs for type 1 diabetes (T1D), type 2 diabetes (T2D), and obesity received major updates.

With so much data coming out of this Q2, the editorial team at HCPLive has collected 9 of the most impactful headlines below. Catch up with any news you may have missed since April:

FDA News

FDA Expands Teplizumab Approval to Children 1 Year & Older to Delay Type 1 Diabetes Onset

On April 22, 2026, parent company Sanofi announced the FDA’s extension of prior approval of teplizumab-mzwv (Tzield) to include children ≥1 year of age with stage 2 type 1 diabetes (T1D) to prevent or delay progression into stage 3 disease. The initial approval was limited to patients ≥8 years; this decision has established teplizumab as the first disease-modifying therapy available for extremely young patients at high risk of developing symptomatic T1D.

FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes

On May 29, 2026, parent company MannKind Therapeutics announced the FDA’s approval of inhaled insulin Afrezza for pediatric patients with either T1D or T2D. Afrezza, the first and only ultra-rapid-acting inhaled insulin with FDA approval for glycemic control in adults with diabetes mellitus, is administered at the start of every meal with a portable inhaler. The drug was first approved in 2014 – in January 2026, the FDA approved an updated label providing clinicians with starting dose guidance when switching from an insulin pump or daily injections.

FDA Proposes Exclusion of Multiple GLP-1 RAs from Bulks List, With Rachael Sood, NP

On April 30, 2026, the FDA announced preliminary plans to remove GLP-1 receptor agonists semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This decision would mark the end of the GLP-1 shortage, as their removal from the list would prevent outsourcing facilities from compounding these drugs. In an interview with HCPLive, Rachael Sood, NP, founder and chief executive officer of the Diabetes Collective and a speaker and clinical expert for Sanofi, Eli Lilly, Dexcom, and others, discussed the broader implications for other GLP-1 medications and other compounded medications at large.

Trial Results

INHALE-1: Afrezza Safe but Misses HbA1c Endpoint in Children With T1D or T2D, With Roy Beck, MD, PhD

Presented at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) by Roy Beck, MD, PhD, the data from this trial provided the backbone for Afrezza’s updated FDA approval for pediatric patients with diabetes. Although inhaled insulin failed to achieve its primary endpoint of HbA1c noninferiority compared to rapid-acting analogue insulin, the combination of positive safety and tolerability data and significantly greater treatment satisfaction established the trial results as positive.

Crinecerfont Reduces Glucocorticoid Doses in CAH, With Richard Auchus, MD, PhD

New data from the CAHtalyst Adult study have reflected that crinecerfont substantially reduces glucocorticoid doses among patients with classic congenital adrenal hyperplasia (CAH), sustaining these reductions over 2 years. The selective oral corticotropin-releasing factor type 1 receptor antagonist was first approved by the FDA in December 2024 to treat CAH in conjunction with glucocorticoids in adults and children ≥4 years.

TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight

Retatrutide, the first triple GIP/GLP-1/glucagon agonist to reach phase 3 clinical trials, has demonstrated significant weight loss in patients with obesity or overweight, according to the TRIUMPH-1 trial. Presented alongside positive data from TRANSCEND-T2D-1 at ADA 2026, this study saw an average weight loss of 64.4 lbs with retatrutide 9 mg and 70.3 lbs with retatrutide 12 mg by week 80. Additionally, 65.3% of patients on retatrutide 12 mg achieved a body mass index <30, the minimum threshold for clinical obesity.

Clinician Insights

Implementing Automated Insulin Delivery in Type 2 Diabetes, With Diana Isaacs, PharmD

At the Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in April, HCPLive spoke with Diana Isaacs, PharmD, director of education and training in diabetes technology at Cleveland Clinic, to discuss the benefits of implementing automated insulin delivery (AID) devices into T2D care. Clinical guidelines have recently shifted to include these devices among treatment recommendations, and recent trials have indicated their efficacy in reducing glycated hemoglobin while increasing time in range.

Ketone Monitoring in Diabetes: Making The Case For When and How to Test

At ADA 2026, HCPLive spoke with Viral Shah, MD, of Indiana University, regarding the importance of – and the shifting attention towards – continuous ketone monitoring. An ADA consensus published prior to the conference established universal diabetes education on ketones as a minimum standard – Shah framed prevention of diabetic ketoacidosis as the central priority of the field, highlighting the critical need to identify elevated ketones early on to intervene.

Berobenatide Monthly Dosing Shows Weight Loss Efficacy in VESPER Trials, With John Buse, MD, PhD

Findings from the VESPER-1 and VESPER-3 trials reflected berobenatide’s efficacy in reducing overweight or obesity in patients with or without T2D. Berobenatide is an investigational ultra-long-acting GLP-1 RA, administered monthly – this substantially reduced dosing frequency, as the trials indicated, can significantly reduce treatment burden and improve treatment adherence and cost.